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Introduction: Emollient therapy is the mainstay for treating skin conditions such as atopic 
dermatitis and psoriasis. New emollients have been introduced recently and are assumed to be 
therapeutically interchangeable with the innovator products because, superficially, they appear to 
have similar compositions. This study compares a) the ex vivo human skin occlusion performance 
and b) the visual and microscopic properties of Isomol gel (IMG) and Doublebase gel (DBG). 
Materials and Methods: Occlusion was measured gravimetrically by reduction in cumulative 
48-hour evaporative weight loss from ex vivo human skin samples following single applications 
of the two test emollients and Vaseline®. Skin samples from a single donor were mounted in 
Franz diffusion cells and then the emollients were spread over the skin surface with an applied 
dose of approximately 2 mg/cm2. The assemblies (four replicates per treatment) were then 
accurately weighed at baseline (T
0
) and again after 5-, 24-, and 48-hour postapplication. The 
quality of the two emollient gel formulations was compared by visual examination of their 
film-forming characteristics and by microstructural examination using environmental scanning 
electron microscopy (ESEM). 
Results: Occlusivity of the DBG emollient gel formulation was comparable with Vaseline 
and substantially better than IMG, with the DBG-treated skin samples losing less than half as 
much weight as the IMG-treated skin samples over 48 hours and at a much slower rate during 
the first 5 hours. The film-forming characteristics and microstructure of the gels were also very 
different. Whereas DBG maintained a smooth, uniform film over 24 hours, the IMG formulation 
phase-separated. ESEM results showed that the DBG emulsion has a stable structural matrix 
with uniform oil droplets, whereas for IMG the emulsion system is inhomogeneous with the 
oil phase coalescing into larger irregular shaped rafts. 
Conclusions: We have demonstrated substantial performance differences between two pre-
scribed emollient gels.
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Introduction
Atopic eczema (AE) is a chronic, relapsing, inflammatory disease affecting up to 
20% of children and young adults.1 A key characteristic of this disease is the loss of 
skin barrier function leading to generalized skin dryness, with some areas exhibiting 
redness and inflammation that invariably become itchy.2
Emollients are essential in the treatment and management of dry skin conditions, 
such as AE, contact dermatitis, and psoriasis.3 Informed selection of emollients is 
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imperative for effective treatment and tends to be based pri-
marily on patient preference and cost.3,4 Innovative and highly 
emollient formulations comprising hydrogel oil emulsions 
with enhanced therapeutic performance and patient appeal4,5 
have been developed. For large historical regulatory reasons, 
these tend to be approved licensed medicines. These emul-
sions are highly regarded among prescribers and patients alike 
because they combine the emollient advantages of ointments 
with the cosmetic advantages of gels.5 Lately, various alterna-
tive products have been introduced.6 However, many of these 
have been developed as self-certified class I medical devices 
and are assumed to be therapeutically interchangeable with 
the innovator products because, superficially, they appear to 
have similar compositions.
The aim of this study was therefore to compare the perfor-
mance of one such class I medical device, Isomol gel (IMG), 
with the innovator licensed medicine with which therapeutic 
equivalence is assumed - based on having similar composi-
tions, namely Doublebase gel (DBG) (Table 1).
Materials and methods
skin occlusion
Use of the ex vivo human skin in this work was formally 
approved by the Research Tissue Bank Ethics Review Board 
(Cardiff, UK). Written informed consents were obtained from 
skin sample donors.
Occlusion was measured by reduction in cumulative 
evaporative weight loss from ex vivo samples of abdomen 
human skin (from a single Caucasian female) during a 
48-hour period, following single applications of the two 
emollient gels, DBG and IMG, and an ointment-positive 
control Vaseline® (pure petroleum jelly; Unilever, UK). 
The latter was chosen because, even though cosmetically 
unacceptable for most atopic dermatitis patients owing 
to its greasiness on the skin and clothing, etc, it is highly 
occlusive.7 Full-thickness ex vivo human skin samples from 
a single donor were mounted in standard Franz diffusion 
cells (unjacketed, 11.28 mm orifice, 2 mL receptor volume; 
SES GmBH – Analysesysteme, Bechenheim, Germany) and 
secured with Parafilm® Film (Bemis North America) and 
stainless steel clips. The receptor chambers of the diffusion 
cells were filled with PBS solution (PBS, pH=7.4; Oxoid Ltd., 
Basingstoke, Hampshire, UK) to bathe the undersides of the 
skin. Four assemblies were prepared for each product/control 
treatment onto which the formulations were applied. Glass 
rods were used to spread the formulations over the exposed 
skin surfaces (discs of approximately 1.1 cm diameter) with 
an applied dose of approximately 2 mg/cm2 surface area of 
skin to mimic normal use. The assemblies were accurately 
weighed immediately after dosing (T
0
) and again after 5, 24, 
and 48 hours using an analytical balance (Sartorius Entris 
124i-1S analytical balance, Germany).
Formulation quality
The quality of the two emollient gel formulations was com-
pared using two methods. First, by observing their visual 
appearance when spread as thin films across glass petri 
dishes, and second by microstructural examination using 
environmental scanning electron microscopy (ESEM).
eseM
All microscopy-related work was performed at Ulster’s Bio-
imaging Core Facility Unit. ESEM was used to escape the 
limitations imposed by conventional high vacuum SEM. The 
combination of differential pumping and pressure limiting 
apertures, in the presence of a gas (water vapor), affords the 
opportunity to nondestructively image samples at relatively 
low vacuum without the need for a conductive coating. With 
Peltier cooling and close control of temperature and pressure, 
water can be maintained in its liquid state, allowing fully 
hydrated samples to be imaged at high magnification and 
spatial resolution.
For ESEM, gel samples were applied in a thin layer onto 
copper (10 mm diameter) ESEM stubs (Agar Scientific, 
Stansted, UK), and these onto the Peltier stage within the 
ESEM. Chamber purge cycle parameters were selected to 
ensure the samples were at equilibrium at a relative humidity 
value of 95%. Temperature (2°C–5°C) and pressure (5.0–6.2 
Torr) were adjusted in real time to ensure a relative humidity 
of 95%. Gels were visualized in an FEI (FEI, Eindhoven, 
Netherlands) Quanta™ ESEM at 30 kV using spot sizes 
4–5 in secondary electron mode, using a gaseous secondary 
electron detector. Images were acquired using the Integrated 
Imaging software.
Table 1 Doublebase and Isomol gels - composition
Doublebase gel
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Results
skin occlusion
Occlusivity of the DBG emollient gel formulation was com-
parable with the positive ointment control and substantially 
better than IMG, with total weight loss from the DBG-treated 
skin assemblies over 48 hours being less than half that from 
IMG-treated skin assemblies (Figure 1).
Considerable weight loss differences between the test 
products were observed even within the first 5 hours of the 
study (Table 2), indicating the superior performances of 
both the Vaseline positive control and DBG by the earliest 
measurement timepoint. Data obtained at the later 24- and 
48-hour timepoints showed similar differences between the 
test products, with the IMG-treated skin assemblies continu-
ing to lose more weight than those for the two other products. 
Overall, this highly occlusive effect of DBG, commencing 
soon after initial product application and lasting for at least 
48 hours following single applications, was very similar to 
the performance of the ointment-positive control. Indeed, by 
expressing the 5-hour weight loss figures as a percentage of 
the total values measured at 48 hours, it is apparent that by 5 
hours the DBG- and Vaseline-treated skin assemblies had lost 
around 32.3% and 40.4%, respectively, of their total weight, 
whereas by 5 hours the IMG-treated skin assemblies had 
already lost as much as 56.5% of their total weight. In other 
words, the DBG-treated skin assemblies lost less weight over 
the full 48 hours and at a substantially slower rate during the 
initial 5 hours. Extrapolating these results to the clinical set-
ting, it therefore follows that although the skin moisturizing 
and barrier effects of DBG are comparable with those of the 
ointment-positive control, this is unlikely to be the case for 
IMG, despite its apparent compositional similarity to DBG.





Average SD Average SD Average SD
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
5 0.0641 0.1083 0.0422 0.0609 0.1348 0.0203
24 0.1289 0.0974 0.1057 0.0530 0.2057 0.0202
48 0.1585 0.0905 0.1306 0.0525 0.2388 0.0181
Abbreviations: DBg, Doublebase gel; IMg, Isomol gel.
Figure 1 Weight loss of three studied formulations over 48-hour period (n=4).
Film-forming characteristics
The film-forming capabilities of the gels were also very dif-
ferent. Whereas DBG maintained a visibly smooth, uniform 
film over 24 hours, a phase separation occurred in the IMG 
formulation, producing a clear liquid (subsequently deter-
mined to be isopropyl myristate, one of the key occlusive 
ingredients in the formulation) (Figure 2).
Microscopy
Microscopic examination revealed significant differences 
between the two emulsion gels. For DBG, the structural 
matrix stabilizing the oil droplets appeared to be uniform with 
most of oil droplets being approximately 2–5 µm in diameter 
(Figure 3). For IMG, however, microscopic examination sug-
gested that the emulsion is largely nonuniform, with the oil 
droplets coalescing into much larger irregular shaped rafts 
of up to 33 µm in diameter (Figure 4).
Discussion
This study has demonstrated that the human skin occlusiv-
ity of the innovator emollient gel formulation, DBG, is very 
similar to that of the ointment-positive control (Vaseline) and 





substantially better than IMG. Weight loss from IMG-treated 
skin assemblies was much faster than that from DBG during 
the first 5 hours after application, and the total weight loss 
over 48 hours was approximately twice than that measured for 
DBG-treated skin. The results also strongly indicate that the 
inferior performance of IMG is explained, at least in part, by 
its inhomogeneous, unstable, and prone to phase-separation 
emulsion, as confirmed by both visual and microscopic 
examination.
For topically applied licensed medicines, there is uni-
versal acceptance that two pharmaceutically similar formu-
lations cannot be assumed to be therapeutically equivalent. 
The regulatory authorities normally require this to be 
demonstrated using comparative clinical trials or appropri-
ate models, as stated in EMA/CHMP/QWP/558185/2014 
guidance. In this study, we have compared the occlusive 
performance of two ostensibly similar formulations and 
shown them to be very different. We have identif ied 
obvious visual and microscopic differences between the 
products, which are likely a reflection of important qualita-
tive and quantitative formulation and production method 
differences, in part explaining the measured performance 
difference.8–10
Whereas licensed medicines are subject to rigorous and 
independent premarketing assessment by the regulatory 
authorities, no such independent assessment of quality, 
safety, and performance applies to self-certified class I 
medical devices, which are registered on the manufacturers’ 
sole responsibility. Formulary administrators, health care 
professionals, prescribers, and patients should bear in mind 
that not all self-certified class I medical devices necessarily 
meet the same standards of quality, safety, and performance 
independently verified for licensed medicines. Therapeutic 
equivalence cannot be assumed between topically applied 
formulations,11,12 even for those that, superficially, may seem 
to be very similar.
Regarding the novel method used to measure occlusiv-
ity, ex vivo human skin is valid for this purpose because the 
primary site of action of emollients on the skin is the external 
stratum corneum, which is nonliving tissue. This therefore 
allows reliable extrapolation in vivo. In addition, by suc-
cessfully mounting samples of skin in Franz cells, this novel 
technique has allowed us to measure the occlusive effect of 
applied emollients directly, by measuring the reduction in 
Figure 2 (A) Films formed by DBg (pink) and (B) IMg (yellow) after 24 hours of exposure to air.
Abbreviations: DBg, Doublebase gel; IMg, Isomol gel.
Figure 3 seM images of (A) DBg and (B) IMg, both at ×4,000 magnification.
Abbreviations: DBg, Doublebase gel; IMg, Isomol gel; seM, scanning electron 
microscopy.
Figure 4 seM images of (A) DBg at ×2,000 and (B) IMg at ×2,400 magnification.
Abbreviations: DBg, Doublebase gel; IMg, Isomol gel; seM, scanning electron 
microscopy.
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weight loss of full-thickness skin post treatment – in this case 
by comparison with a positive control. To our knowledge, 
this direct measurement approach on human skin has not 
previously been reported and offers a new, objective measure 
of emollient performance, as an alternative or supplement 
to corneometry and TEWL methods which, although well 
established, are mainly confined to use in time-consuming 
and costly clinical trials. Using the novel gravimetric method 
described herein, it may also be possible to compare more 
products in individual studies than is generally feasible using 
in vivo methodology. This may usefully encourage more 
research into this important therapeutic area, as requested 
by National Institute for Health and Clinical Excellence 
(NICE).13
Conclusion
For topically applied formulations, it is very important that 
they are formulated and manufactured such that their full 
clinical benefit can be realized. By using objective instru-
mental measurements, we have demonstrated substantial 
performance differences between two prescribed emollient 
gels. Although the DBG and IMG formulations tested here 
may seem to be similar, they should not be regarded as being 
therapeutically interchangeable. Class I medical devices are 
self-certified and have no formal, independent assessment 
of their quality, safety, or performance. With this work, we 
have identified important shortcomings that need to be taken 
into consideration before assuming interchangeability based 
solely on the list of ingredients.
Acknowledgments
We would like to acknowledge Dermal Laboratories Ltd, 
Hitchin, UK, for providing product samples for this study. 
The abstract of this paper was presented at the fifth Annual 
International Conference on Chemistry as a conference talk 
with interim findings. The abstract was published in Abstract 
Book: 5th Annual International Conference on Chemistry; 
ISBN: 978-960-598-161-7.
Disclosure
The authors report no conflicts of interest in this work. 
References
 1. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR, 
International Study of Asthma and Allergies in Childhood (ISAAC) 
Phase One and Three Study Groups. Is eczema really on the increase 
worldwide? J Allergy Clin Immunol. 2008;121(4):947–954.
 2. Kownacki S. The importance of emollients in treating the increasing 
incidence of atopic eczema. Nurs Times. 2009;105(28):18–22.
 3. Moncrieff G, Cork M, Lawton S, Kokiet S, Daly C, Clark C. Use of 
emollients in dry-skin conditions: consensus statement. Clin Exp Der-
matol. 2013;38(3):231–238.
 4. Cork MJ. Complete emollient therapy. In: Tod D, editor. National Asso-
ciation of Fundholding Practices Yearbook. Thornton Heath, Surrey, 
UK: Scorpio Publishing; 1998:159–168.
 5. Wynne A, Whitefield M, Dixon AJ, Anderson S. An effective, cosmeti-
cally acceptable, novel hydro-gel emollient for the management of dry 
skin conditions. J Dermatolog Treat. 2002;13(2):61–66.
 6. IMS sales data audit, British Pharmaceutical Index (BMI); 2018. 
Accessed July 03, 2018.
 7. Clarke C. Atopic eczema clinical features and diagnosis. Clin Pharm. 
2010;2:285–289.
 8. Chang RK, Raw A, Lionberger R, Yu L. Generic development of topical 
dermatologic products: formulation development, process development, 
and testing of topical dermatologic products. Aaps J. 2013;15(1):41–52.
 9. Nalamothu V. Topical delivery - the importance of the right formulation 
in topical drug development. Drug Development Delivery. 2015:1–4.
 10. Nwoko VE. Semi solid dosage forms manufacturing: tools, critical 
process parameters, strategies, optimization and validation. Sch Acad 
J Pharm. 2014;3(2):153–161.
 11. Ersser S, Maguire S, Nicol N, et al. A best practice statement for emol-
lient therapy. Dermatol Nurs. 2007;6(4):2–19.
 12. Voegeli D. The vital role of emollients in the treatment of eczema. Br 
J Nurs. 2011;20(2):74–80.
 13. NICE. Management of atopic eczema in children from birth up to the 
age of 12 years: National Institute for Health and Clinical Excellence. 
London, UK: RCOG Press; 2007:CG57.
